Respiratory Syncytial Virus clinical trials at University of California Health
4 in progress, 3 open to eligible people
A Clinical Study for Infants and Toddlers Diagnosed with Respiratory Syncytial Virus (RSV)
“Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”
open to eligible people ages up to 36 months
A 2-part study to evaluate the safety, pharmacokinetics and efficacy of EDP-938 in children with RSV infection.
at UC Davis UCLA
Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
open to eligible people ages up to 2 years
The overarching hypothesis of the ARRC trial is that administration of Azithromycin (AZM) during acute, Respiratory Syncytial Virus (RSV)-induced respiratory failure will be beneficial, mediated through the matrix metalloproteinase (MMP)-9 pathway.
at UCSF
Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age
open to eligible people ages 6 months to 25 months
The purpose of this study is to evaluate the safety and immunogenicity of a single dose of the recombinant live-attenuated respiratory syncytial virus (RSV) vaccines, RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, and RSV 276, in RSV-seronegative children 6 to 24 months of age.
at UCLA UCSD
Are you pregnant? Participate in a vaccine study trying to protect babies from Respiratory Syncytial Virus!
“Pass on what's important: You’ll give them love in lots of ways. Could protection from RSV be one of them?”
Sorry, in progress, not accepting new patients
This randomized, double-blinded, placebo-controlled Phase 3 study is designed to evaluate the efficacy and safety of maternal immunization with RSVpreF against medically attended lower respiratory tract illness (MA-LRTI) in infants.
at UCLA
Last updated: